Effect of Radiotherapy Variables on Circulating Effectors of Immune Response and Local Microbiome

Cohort 1a and b: Prostate cancer subjects undergoing 9 week radiation

Inclusion criteria:

Biopsy-proven diagnosis of prostate adenocarcinoma
Age ≥ 18

Exclusion criteria:

History of prior pelvic radiation (external beam or brachytherapy)
Prior or concurrent lymphomatous/hematogenous malignancy, or history of prior/concurrent invasive malignancy during the past 5 years
History of hormone therapy such as LHRH agonists (gosrelin, leuprolide), anti-androgens (flutamide, bicalutamide), surgical castration (orchiectomy)
History of irritable bowel disease
Evidence of lymph node involvement or metastatic disease

Cohort 2a : Breast cancer subjects undergoing standard fractionation RT of 5 weeks

Inclusion criteria:

Biopsy-proven diagnosis of invasive breast cancer, s/p breast surgery to negative margins, and requiring adjuvant breast and nodal RT
Age ≥ 18

Exclusion criteria:

History of prior radiation therapy to the ipsilateral breast
Prior or concurrent lymphomatous/hematogenous malignancy, or history of prior/concurrent invasive malignancy during the past 5 years
< 1 month from completion of chemotherapy to start of RT
Evidence of metastatic disease

Cohort 2b: Breast cancer subjects undergoing PBI

Inclusion criteria:

Post-menopausal women defined as either 1) at least 2 years without menstrual period or 2) or patients older than 50 with serological evidence of post-menopausal status or 3) hysterectomized patients of any age with FSH confirmation of post-menopausal status.
Post-segmental mastectomy with negative margins
If bilateral, pT1 breast cancer, excised with negative margins AND/OR
pTis excised with negative margins
Clinically N0 or pN0 or sentinel node negative
Diagnosis of ductal carcinoma in situ DCIS, limited to <2cm size of DCIS and to lesions of low or intermediate grade, excised (or re-excised) with final negative margins ( no DCIS on inked margins).
Age ≥ 18

Exclusion criteria:

History of prior radiation therapy to the ipsilateral breast
Presence of a proportion of DCIS in the core biopsy specimen which is compatible with extensive intraductal component (EIC).
< 1 month from completion of chemotherapy to start of RT
Evidence of metastatic disease